

Emergent BioSolutions Inc.  
Form 8-K  
March 13, 2013  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 12, 2013

Emergent BioSolutions Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware                       001-33137   14-1902018  
(State or Other Jurisdiction (Commission (IRS Employer  
of Incorporation)            File Number) Identification No.)

2273 Research Boulevard, Suite 400, Rockville, Maryland 20850  
(Address of Principal Executive Offices)                                 (Zip Code)

Registrant's telephone number, including area code: (301) 795-1800

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective April 1, 2013, Emergent BioSolutions Inc. elected Steven N. Chatfield, Ph.D. to the new position of Executive Vice President, Strategic Investments. Since January 2012 he has served as Executive Vice President, Biosciences. In this new position, Dr. Chatfield will no longer be subject to the reporting requirements under Section 16 of the Securities Exchange Act of 1934. Except for his new position as Executive Vice President, Strategic Investments, the terms of Dr. Chatfield's employment arrangement with the company have not changed. Dr. Chatfield's employment agreement, which was filed as Exhibit 10.11 to the company's Annual Report on Form 10-K filed on March 9, 2012, and is incorporated herein by reference, will remain in place.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 13, 2013 EMERGENT  
BIOSOLUTIONS  
INC.  
By: /s/ Jay G. Reilly  
Jay G. Reilly  
General Counsel